Integer initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Integer with an Outperform rating and $135 price target. Integer is the market leader in medical device outsourcing, with “unique expertise along the product life cycle chain” as well as a “broad base of blue-chip customers,” the analyst tells investors. Its customer list plus the long-term nature of 70% of its contracts give the Integer story automatic “buffers” for risk mitigation, the analyst added.